Page 140 - 2019_08-Haematologica-web

M. Takeuchi et al.
1 and programmed death-1 ligand-2 expres-
sion in human esophageal cancer. Clin
Cancer Res. 2005;11(8):2947-2953.
8. Thompson RH, Dong H, Kwon ED. Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostica- tion and therapy. Clin Cancer Res.
2007;13(2);709-715.
9. Zou W, Chen L. Inhibitory B7-family mole-
cules in the tumour microenvironment. Nat
Rev Immunol. 2008;8(6):467-477.
10. Miyoshi H, Kiyasu J, Kato T, et al. PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma. Blood.
2016;128(10):1374-1381.
11. Hicklin DJ, Wang Z, Arienti F, et al. β2-
microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. J Clin Invest. 1998;101(12);2720-2729.
12. Kataoka K, Nagata Y, Kitanaka A, et al. Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat Genet. 2015;47 (11):1304-1315.
13. Asano N, Miyoshi H, Kato T, et al. Expression pattern of immunosurveillance- related antigen in adult T cell leukaemia/ lymphoma. Histopathology. 2018;72(6): 945-954.
14. Keir ME, Francisco LM, Sharpe AH. PD-1 and its ligands in T-cell immunity. Curr Opin Immunol. 2007;9(3):309-314.
15. Pedoeem A, Azoulay-Alfaguter I, Strazza M, et al. Programmed death-1 pathway in can- cer and autoimmunity. Clin Immunol. 2014;153(1):145-152.
16. Melief CMJ. Precision T-cell therapy targets tumours. Nature. 2017;547(7662):217-222.
17. Seliger B. Molecular mechanisms of HLA class I-mediated immune evasion of human tumors and their role in resistance to immunotherapies. HLA. 2016;88(5): 213- 220.
18.
19.
20.
21.
22.
23. 24.
25.
Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015; 372(4):311-319.
Reichel J, Chadbum A, Rubunstein PG, et al. Flow sorting and exome sequencing reveal the oncogene of primary Hodgkin and Reed- Sternberg cells. Blood. 2015;125(7):1061- 1072.
Sconocchia G, Eppenberger-Castori S, Zlobec I, et al. HLA class II antigen expres- sion in colorectal carcinoma tumors as a favorable prognostic marker. Neoplasia. 2014;16(1):31-42.
Esteban F, Ruiz-Cabello F, Concha A, et al. HLA-DR expression is associated with excellent prognosis in squamous cell carci- noma of the larynx. Clin Exp Metastasis. 1990;8(4):319-328.
Rimsza LM, Robberts RA, Campo E, et al. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosur- veillance and poor patient survival regard- less of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood. 2004;103(11):4251-4258.
He Y, Rozeboomb L, Rivardb CJ, et al. MHC class II expression in lung cancer. Lung Cancer. 2017;112:75-80.
Johnson DB, Estrada MV, Salgado R, et al. Melanoma-specific MHC-II expression represents a tumour-autonomous pheno- type and predicts response to anti-PD- 1/PD-L1 therapy. Nat Commun. 2016;29 (7):10582.
Roemer MG, Advani RH, Redd RA, et al. Classical Hodgkin lymphoma with reduced β2M/MHC class I expression is associated with inferior outcome independent of 9p24.1 status. Cancer Immunol Res. 2016;4(11):910-916.
26. Roemer MGM, Redd RA, Cader FZ, et al. Major histocompatibility complex class II and programmed death ligand expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma. J Clin Oncol. 2018; 36(10):942-950.
27. Ratner L, Waldman TA, Janakiram M, et al. Rapid progression of adult T-cell leukemia- lymphoma after PD-1 inhibitor therapy. N Engl J Med. 2018;378(20):1947-1948.
28. Weisenburger DD1, Savage KJ, Harris NL, et al. International Peripheral T-cell Lymphoma Project. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood. 2011;117(12): 3402-3408.
29. Fukushima T, Nomura S, Shimoyama M, et al. Japan Clinical Oncology Group (JCOG) prognostic index and characterization of long term survivors of aggressive adult T cell leukaemia lymphoma (JCOG0902A). Br J Haematol. 2014;166(5):739-748.
30. SunZ.ChenF,MengF,WeiJ,LiuB.MHC class II restricted neoantigen: a promising target in tumor immunotherapy. Cancer Let. 2017;392:17-25.
31. Holling TM, Schooten E, Langerak AW, van den Elsen PJ. Regulation of MHC class II expression in human T-cell malignancies. Blood. 2004;103(4):1438-1444.
32. Forlani G, Abdallah R, Accol RS, Tosi G. The major histocompatibility complex class II transactivator CIITA inhibits the persistent activation of NF-κB by the human T cell lymphptropic virus type 1 Tax-1 oncopro- tein. J Virol. 2016;90(7):3708-3721.
33. Shirono K, Hattori T, Hata H, Nishimura H, Takatsuki K. Profiles of expression of acti- vated cell antigens on perioheral blood and lymph node cells from different clinical stages of sdult T-cell leukemia. Blood. 1989;73(6):1664-1671.
1632
haematologica | 2019; 104(8)